Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Christie Ballantyne MD

Christie M. Ballantyne MD

Chief, Section of Cardiovascular Research; Director, Center for Cardiometabolic Disease Prevention; Professor of Medicine and Molecular and Human Genetics; Baylor College of Medicine, Houston, TX

Christie M. Ballantyne, MD, is an internationally renowned expert on lipids, atherosclerosis and heart disease prevention. He is the Chief of Cardiovascular Research and the Director of Cardiometabolic Disease Prevention at Baylor College of Medicine.

Dr. Ballantyne's research in the prevention of heart disease led him to become an established investigator for the American Heart Association. Since 1988, Dr. Ballantyne has received continuous funding from the National Institutes of Health to support his basic research of leukocyte-endothelial interactions, translational biomarkers and clinical trials.

Clarivate Web of Science named Dr. Ballantyne as a “Highly Cited Researcher” from 2017 to 2022, being in the top 1% of the most-cited investigators. This distinction is based on his 800-plus journal publications in the areas of atherosclerosis, lipids and inflammation. His research has led to the U.S. Food and Drug Administration's approval of 2 biomarkers for cardiovascular risk prediction, and he has played a prominent role in the development and approval of new lipid-lowering therapies.

Dr. Ballantyne's many professional accomplishments include being elected Fellow of the American Association for the Advancement of Science, the American Society of Clinical Investigation, and the Association of American Physicians. He serves on the Editorial Board of Circulation and the Journal of the American College of Cardiology, and in 2012 he received the Distinguished Scientist Award from the American College of Cardiology.


Grant/Research Support- All significant. (All paid to institution, not individual): Abbott Diagnostic, Akcea, Amgen, Arrowhead, Ionis, Merck, New Amsterdam, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, NIH, AHA, ADA.

Consultant- Abbott Diagnostics, Alnylam Pharmaceuticals, Amgen, Arrowhead, Astra Zeneca, Denka Seiken*, Eli Lilly, Esperion, Genentech, Illumina, Ionis, Merck, New Amsterdam*, Novartis, Novo Nordisk, Roche Diagnostic, TenSixteen Bio

*Significant where noted (>$10,000); remainder modest (<$10,000).